Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|August 30, 2018
Considering Triplet Therapy for Nondriver NSCLC
Considering Triplet Therapy for Nondriver NSCLC
Advertisement
A 64-Year-Old Woman With Metastatic NSCLC
- A 64-year-old woman reported having cough and shortness of breath on exertion for the past 2 years, but now having persistent symptoms even without exertion.
- PE: revealed diminished breath sounds and minimal expiratory wheezing in right lung; not physically fit
- PMH: mild hypertension well managed on lisinopril
- SH: smoker, 15 pack-years
- CT scan revealed 2 masses in RUL and several small masses in the liver
- Biopsy of right lung mass confirmed grade 2 adenocarcinoma
- EGFRnegative,KRASnegative
- IHC negative forALK-rearrangement,ROS1-rearrangement
- PD-L1 TPS: 56%
- PET scan showed multiple areas of FDG uptake in liver, SUVmax, 7.8
- Brain MRI, negative for metastases
- Diagnosis: stage IV lung adenocarcinoma
- Patient started on treatment with pembrolizumab/pemetrexed/carboplatin
Advertisement
Related to this article
The NDA was completed for first-line zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion NSCLC, based on phase 3 REZILIENT3 data showing improved PFS.
Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
5